Overview
Sail Biomedicines creates programmable RNA medicines that enable in vivo CAR-T therapies for autoimmune diseases, turning the patient’s body into the site of T-cell engineering. Its platform combines Endless RNA circular RNA, a library of targeted nanoparticles for cell-specific delivery, and AI-powered design tools to program T cells inside the body. It differentiates from competitors by delivering and programming CAR-T cells in vivo rather than via ex vivo cell manufacturing, leveraging circular RNA and targeted nanoparticles, with support from its Flagship Pioneering lineage and a Johnson & Johnson collaboration. The goal is to provide scalable, durable immune resets and remission for immune-mediated diseases with broader, more accessible treatments.
Work here?Claim your company
Simplify's take
What believers are saying
- J&J committed $785 million upfront, including $465 million equity, on July 29, 2026.
- Gene Marcantonio became CMO in 2026, strengthening clinical execution before first-in-human studies.
- Sail's April 2026 data support an IND path for autoimmune in vivo CAR-T programs.
What critics are saying
- Sail remains preclinical, so human safety and efficacy remain unproven before 2027.
- J&J's transaction still needs regulatory approvals, and option exercise depends on milestones.
- Off-target T-cell programming or cytokine toxicity can destroy the platform and kill acquisition value.
What makes Sail Biomedicines unique
- Sail combines eRNA circular RNA and targeted nanoparticles into one programmable delivery engine.
- Johnson & Johnson secured a $2.58 billion acquisition option on July 29, 2026.
- April 2026 primate data showed deep B-cell depletion across blood, bone marrow, lymph nodes.
Help us improve and share your feedback! Did you find this helpful?